MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Home・Aandelen Lijst・Altimmune Inc

Altimmune Inc

Open

4.85 14.12

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.32

Max

4.86

Belangrijke statistieken
By Trading Economics
Inkomsten	3.1M -19M
Verkoop	5K
Winstmarge	-380,280
Werknemers	59
EBITDA	4.4M -18M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+207.33% upside

Dividenden
By Dow Jones
Volgende Winsten	26 mrt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	93M 442M
Vorige openingsprijs	-9.27
Vorige sluitingsprijs	4.85

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

5.365 / 6.0486 Steun & Weerstand

Altimmune Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 jan 2026, 23:49 UTC

Belangrijke Marktbewegers

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21 jan 2026, 21:12 UTC

Belangrijke Marktbewegers

Automaker Stocks Rise After Trump Calls Off European Tariffs

21 jan 2026, 21:00 UTC

Acquisities, Fusies, Overnames

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21 jan 2026, 20:29 UTC

Belangrijke Marktbewegers

Chip Makers Gain After Trump Calls Off European Tariffs

21 jan 2026, 20:04 UTC

Belangrijke Marktbewegers

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21 jan 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21 jan 2026, 23:34 UTC

Marktinformatie

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21 jan 2026, 22:39 UTC

Winsten

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21 jan 2026, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

21 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

21 jan 2026, 21:35 UTC

Acquisities, Fusies, Overnames

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21 jan 2026, 21:19 UTC

Winsten

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21 jan 2026, 20:45 UTC

Acquisities, Fusies, Overnames

Deutsche Borse Group to Acquire Allfunds for $6.19B

21 jan 2026, 20:36 UTC

Marktinformatie

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21 jan 2026, 20:31 UTC

Marktinformatie

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21 jan 2026, 20:27 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21 jan 2026, 20:27 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

21 jan 2026, 20:27 UTC

Marktinformatie

Was It a 'TACO' Event? -- Market Talk

21 jan 2026, 20:26 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21 jan 2026, 20:23 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21 jan 2026, 20:21 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21 jan 2026, 20:19 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse Group Agrees to Buy Allfunds

21 jan 2026, 20:08 UTC

Winsten

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21 jan 2026, 20:03 UTC

Marktinformatie

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21 jan 2026, 19:51 UTC

Marktinformatie

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21 jan 2026, 19:43 UTC

Marktinformatie

U.S. Ethanol Production Expected to Slip -- Market Talk

21 jan 2026, 19:31 UTC

Marktinformatie

Gold Settles at Fresh All-Time High -- Market Talk

21 jan 2026, 19:24 UTC

Winsten

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 jan 2026, 19:10 UTC

Marktinformatie

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21 jan 2026, 18:57 UTC

Marktinformatie

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Peer Vergelijking

Prijswijziging

Altimmune Inc Prognose

Koersdoel

By TipRanks

207.33% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 13 USD 207.33%

Hoogste 14 USD

Laagste 12 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Altimmune Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Altimmune Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.365 / 6.0486Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.